Spanja - Spanjol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

boehringer ingelheim vetmedica gmbh - proteina orf2 de circovirus porcino tipo 2 - suspensiÓn inyectable - excipientes: carbomero, cloruro de sodio, agua para preparaciones inyectables - vacunas víricas inactivadas - porcino

Spanja - Spanjol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

boehringer ingelheim vetmedica gmbh - proteina orf2 de circovirus porcino tipo 2 - suspensiÓn inyectable - excipientes: carbomero, agua para preparaciones inyectables, cloruro de sodio - vacunas víricas inactivadas - porcino

Unjoni Ewropea - Spanjol - EMA (European Medicines Agency)

intervet international bv - antígeno de la subunidad orf2 del circovirus porcino tipo 2 - inmunológicos para suidos - cerdos - para la inmunización activa de cerdos para reducir la carga viral en sangre y tejidos linfoides y para reducir la pérdida de peso asociada con la infección por circovirus tipo 2 porcino que ocurre durante el período de engorde. inicio de la inmunidad: 2 weeksduration de la inmunidad: 22 semanas.

Spanja - Spanjol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

intervet international bv - proteina orf2 de circovirus porcino tipo 2 - emulsiÓn inyectable - excipientes: simeticona, cloruro de sodio, cloruro potasico, hidrogenofosfato de disodio dihidrato, dihidrogenofosfato de potasio, acetato de dl-alfa-tocoferilo, parafina liquida ligera, agua para preparaciones inyectables, polisorbato 80 - circovirus porcino - cerdos de engorde

Spanja - Spanjol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

intervet international bv - proteina orf2 de circovirus porcino tipo 2 - emulsiÓn inyectable - excipientes: polisorbato 80, simeticona, cloruro de sodio, cloruro potasico, hidrogenofosfato de disodio dihidrato, dihidrogenofosfato de potasio, acetato de dl-alfa-tocoferilo, parafina liquida ligera, agua para preparaciones inyectables - circovirus porcino - cerdos de engorde

Spanja - Spanjol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

intervet international bv - proteina orf2 de circovirus porcino tipo 2 - emulsiÓn inyectable - excipientes: simeticona, cloruro de sodio, cloruro potasico, hidrogenofosfato de disodio dihidrato, dihidrogenofosfato de potasio, acetato de dl-alfa-tocoferilo, parafina liquida ligera, agua para preparaciones inyectables, polisorbato 80 - circovirus porcino - cerdos de engorde

Spanja - Spanjol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

intervet international bv - proteina orf2 de circovirus porcino tipo 2 - emulsiÓn inyectable - excipientes: polisorbato 80, simeticona, cloruro de sodio, cloruro potasico, hidrogenofosfato de disodio dihidrato, dihidrogenofosfato de potasio, acetato de dl-alfa-tocoferilo, parafina liquida ligera, agua para preparaciones inyectables - circovirus porcino - cerdos de engorde

Unjoni Ewropea - Spanjol - EMA (European Medicines Agency)

intervet international b.v. - antígeno de la subunidad orf2 del circovirus porcino tipo 2 - immunologicals for suidae, inactivated viral vaccines - cerdos - for the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues and virus shedding caused by pcv2 infection.  to reduce loss of daily weight gain and mortality associated with pcv2 infection.

Unjoni Ewropea - Spanjol - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - inmunológicos para suidos - los cerdos (de engorde) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Unjoni Ewropea - Spanjol - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - cerdos - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.